An overview of the publications and thought leadership PricewaterhouseCoopers produces by their Global Pharmaceuticals and life sciences industry practice professionals. en-gx Tue, 10 Jun 2003 04:00:00 GMT Thu, 20 Jun 2013 01:24:08 EDT http://www.pwc.com/ http://www.pwc.com//en_GX/webadmin/assets/image/pwclogo.gif http://cyber.law.harvard.edu/rss/rss.html PricewaterhouseCoopers WCPS PricewaterhouseCoopers PricewaterhouseCoopers This publication is designed to help pharmaceutical and life sciences companies understand how the upcoming US GAAP changes and the joint revenue recognition project potentially could affect their businesses.

]]> PwC recently surveyed executives from leading global and domestic Medtech companies with India operations representing $1.3 billion in revenues in India, or roughly 40% of the $3 billion Indian market. Their responses, combined with in-depth interviews and PwC’s research and experience in the industry, provide insight on how to succeed in India.

]]> PwC discusses the accounting for some of the issues faced by the medical technology industry.

]]> According to our 2011 Global CEO Survey, competitive threats, industry dynamics and regulation are the most important factors driving change for pharma and life sciences CEOs.

]]> Pharmaceutical companies commonly pay royalties related to the right to make, use, and/or sell products based on patented biological or chemical know-how, where the amount of the royalty payment is based on a percentage of the revenue from the sale of products and is incurred only when the products are sold.

]]> Poland remains the largest clinical trials market in CEE/CIS, however, both patient participation and site penetration rates indicate a potential for growth. Launching a number of initiatives will accelerate the market growth and maximize the potential benefits to the economy.

]]> Biotech reinvented

]]> How will IFRS 3 affect pharmaceutical and life sciences? For one, it may introduce more volatility into an acquirer's income statement. Here, we explain the changes and offer examples of how the issue may impact your company

]]> Venture capital (VC) funding in the Life Sciences sector, which includes the biotechnology and medical device industries had record dollars in Q2 2010. Find out where the money went in PwC's MoneyTree report - based on Thomson Reuters data.

]]> US Healthcare reform has raised some significant accounting issues for the pharmaceutical and life sciences sector, including the annual fee on pharmaceutical manufacturers and the excise tax on medical device manufacturers

]]>